Fredag 27 December | 16:11:50 Europe / Stockholm

Kalender

Tid*
2026-02-02 08:00 Bokslutskommuniké 2025
2025-10-23 08:00 Kvartalsrapport 2025-Q3
2025-07-15 08:00 Kvartalsrapport 2025-Q2
2025-05-08 N/A Årsstämma
2025-04-25 08:00 Kvartalsrapport 2025-Q1
2025-02-05 08:00 Bokslutskommuniké 2024
2024-10-23 - Kvartalsrapport 2024-Q3
2024-07-15 - Kvartalsrapport 2024-Q2
2024-05-10 - X-dag ordinarie utdelning ALIF B 0.50 SEK
2024-05-08 - Årsstämma
2024-04-24 - Kvartalsrapport 2024-Q1
2024-02-02 - Bokslutskommuniké 2023
2023-10-26 - Kvartalsrapport 2023-Q3
2023-07-14 - Kvartalsrapport 2023-Q2
2023-05-05 - X-dag ordinarie utdelning ALIF B 1.20 SEK
2023-05-04 - Årsstämma
2023-04-26 - Kvartalsrapport 2023-Q1
2023-02-02 - Bokslutskommuniké 2022
2022-10-27 - Kvartalsrapport 2022-Q3
2022-07-15 - Kvartalsrapport 2022-Q2
2022-05-06 - X-dag ordinarie utdelning ALIF B 2.00 SEK
2022-05-05 - Årsstämma
2022-04-28 - Kvartalsrapport 2022-Q1
2022-02-04 - Bokslutskommuniké 2021
2021-10-22 - Kvartalsrapport 2021-Q3
2021-07-15 - Kvartalsrapport 2021-Q2
2021-05-06 - X-dag ordinarie utdelning ALIF B 1.50 SEK
2021-05-05 - Årsstämma
2021-04-28 - Kvartalsrapport 2021-Q1
2021-02-03 - Bokslutskommuniké 2020
2020-11-20 - X-dag ordinarie utdelning ALIF B 0.50 SEK
2020-11-20 - X-dag bonusutdelning ALIF B 0.5
2020-11-19 - Extra Bolagsstämma 2020
2020-10-22 - Kvartalsrapport 2020-Q3
2020-07-17 - Kvartalsrapport 2020-Q2
2020-05-27 - Split ALIF B 1:4
2020-05-08 - X-dag ordinarie utdelning ALIF B 2.40 SEK
2020-05-07 - Årsstämma
2020-04-28 - Kvartalsrapport 2020-Q1
2020-02-06 - Bokslutskommuniké 2019
2019-11-07 - Kvartalsrapport 2019-Q3
2019-07-12 - Kvartalsrapport 2019-Q2
2019-05-10 - X-dag ordinarie utdelning ALIF B 2.20 SEK
2019-05-09 - Årsstämma
2019-05-09 - Kvartalsrapport 2019-Q1
2019-02-12 - Bokslutskommuniké 2018
2018-12-20 - Extra Bolagsstämma 2018
2018-11-07 - Kvartalsrapport 2018-Q3
2018-07-13 - Kvartalsrapport 2018-Q2
2018-06-01 - X-dag ordinarie utdelning ALIF B 2.20 SEK
2018-05-31 - Årsstämma
2018-04-27 - Kvartalsrapport 2018-Q1
2018-02-13 - Bokslutskommuniké 2017
2017-10-26 - Kvartalsrapport 2017-Q3
2017-07-17 - Kvartalsrapport 2017-Q2
2017-05-30 - X-dag ordinarie utdelning ALIF B 1.50 SEK
2017-05-29 - Årsstämma
2017-04-28 - Kvartalsrapport 2017-Q1
2017-02-16 - Bokslutskommuniké 2016
2016-10-27 - Kvartalsrapport 2016-Q3
2016-09-02 - X-dag ordinarie utdelning ALIF B 0.00 SEK
2016-09-01 - Årsstämma
2016-07-15 - Kvartalsrapport 2016-Q2

Beskrivning

LandSverige
ListaLarge Cap Stockholm
SektorHälsovård
IndustriMedicinteknik
AddLife är en koncern med verksamhet inom life-science sektorn. Inom koncernen återfinns specialisering främst mot diagnostik, medicinteknik och biomedicinsk forskning. Verksamhet innehas främst i Norden och Baltikum med kunder inom vård och omsorg, samt forskningsinstitut. Addlife bildades under 2015 vid en avknoppning ur Addtech koncernen. Bolaget har sitt huvudkontor i Stockholm.
2023-02-02 07:45:00

Increased organic growth in both business areas

AddLife´s year-end report for Q4 2022 is now available online at the company website. The year-end report can be downloaded in pdf version. Visit https://reports-en.add.life/year-end-report-q4-2022

1 OCTOBER – 31 DECEMBER 2022 (3 MONTHS)

  • Net sales increased by 9 percent to SEK 2,326m (2,131), of which acquired growth amounted to 12 percent. The COVID-19 related net sales decreased by 82 percent. The organic growth, excluding net sales related to COVID-19, was 6 percent.
  • EBITA amounted to SEK 258m (329), corresponding to an EBITA-margin of 11.1 percent (15.5).
  • Profit after tax amounted to SEK 62m (178).
  • Earnings per share amounted to SEK 0.50 (1.46).  
  • Cash flow from operating activities amounted to SEK 351m (393).

1 JANUARY – 31 DECEMBER 2022 (12 MONTHS)

  • Net sales increased by 14 percent to SEK 9,084m (7,993), of which acquired growth amounted to 22 percent. The COVID-19 related net sales decreased by 62 percent. The organic growth, excluding net sales related to COVID-19, was 4 percent.
  • EBITA amounted to SEK 1,221m (1,273), corresponding to an EBITA-margin of 13.4 percent (15.9). EBITA includes a reversed contingent consideration of SEK 101m, excluding this, EBITA margin amounted to 12.3 percent.
  • Profit after tax amounted to SEK 483m (721).
  • Earnings per share amounted to SEK 3.96 (6.03). 
  • Cash flow from operating activities amounted to SEK 909m (1,010).
  • The equity ratio was 38 percent (40).
  • Return on working capital (P/WC) amounted to 61 percent (95).
  • During the year, five acquisitions were completed. The acquisitions are expected to contribute with annual net sales of approximately SEK 850m.
  • The Board of directors proposes a dividend of SEK 1.20 per share.

Stockholm, February 2, 2023
AddLife AB (publ)

For more information, contact;
Fredrik Dalborg, CEO, fredrik.dalborg@add.life, +46 70 516 09 01 
Christina Rubenhag, CFO, christina.rubenhag@add.life, +46 70 546 72 22
www.add.life

Teleconference
Investors, analysts and the media are invited to a teleconference at which CEO Fredrik Dalborg and CFO Christina Rubenhag will present the year-end report. The presentation will be given in English and take about 20 minutes. after which there will be an opportunity to ask questions. The meeting will be recorded and made available online. If this is your first time using Teams, you will be asked to download an app.

The teleconference will be at 10 a.m. CET on February 2, 2023
If you wish to participate via teleconference, please follow this link>> 
Or call in (only sound) +46 8 505 376 58 Conference-ID: 427 903 522#

The presentation is also available on AddLife YouTube >>


AddLife is an independent player in the Life Science industry that offers high-quality products, services and advice to both the private and public sectors, mainly in the Nordic region and rest of Europe. AddLife has about 2,200 employees in some 85 operating subsidiaries. The Group currently has net sales of approximately SEK 9 billion. AddLife shares are listed on Nasdaq Stockholm.

This information is information that AddLife AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact person set out above, at February 2, 2023 at 07:45 a.m. CET.